PROCEPT BioRobotics Corporation reports developments in surgical robotics for urology, centered on its AQUABEAM and HYDROS Robotic Systems and Aquablation therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia. Company news commonly covers financial results, system sales and procedure trends, commercial execution, pricing and inventory commentary, and investment in its BPH platform technology.
Updates also include product clearances such as FirstAssist AI software, international launch activity for HYDROS, clinical evidence and guideline recognition for Aquablation therapy, investor presentations, and research activity including the WATER IV prostate cancer trial.
PROCEPT BioRobotics (Nasdaq: PRCT) management will join a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. The discussion is scheduled for 3:30 p.m. ET in New York City, where the company will also host in-person meetings.
A live webcast will be available on the company's investor website, with a replay available for at least 90 days after the event.
PROCEPT BioRobotics (PRCT) reported third-quarter 2026 revenue of $98.3 million, up 18% year over year, and reaffirmed full-year guidance. U.S. procedures exceeded 13,400, up approximately 22%. U.S. handpiece and consumable revenue rose 21% to $53.9 million, while international revenue increased 32% to $12.5 million.
Gross margin reached 66%, versus 65% a year earlier, but operating expenses increased to $92.5 million from $77.2 million. Net loss widened to $26.5 million from $21.4 million; adjusted EBITDA, a non-GAAP earnings measure, was a $9.8 million loss versus $7.4 million.
The company continues to expect 2026 revenue of $390 million–$410 million, growth of 27%–33%, and 54,000–56,000 U.S. procedures, growth of 25%–29%. It also reaffirmed approximately 65% gross margin and an adjusted EBITDA loss of $35 million to $30 million.
PROCEPT BioRobotics (Nasdaq: PRCT) will report third-quarter 2026 financial results after market close on November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time. Live audio and an archived recording will be available through the company's investor website, with replay available for at least 90 days after the event.
PROCEPT BioRobotics (Nasdaq: PRCT) announced that members of its management team will present and host investor meetings at the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026. Investors can view the presentation or request meetings through their Baird representative.
PROCEPT BioRobotics (Nasdaq: PRCT) reported second quarter 2026 revenue of $94.5 million, up 19% year over year, driven by higher U.S. handpiece, system, and international revenue. U.S. revenue grew 20% to $83.4 million, including $48.4 million from handpieces and consumables and $29.1 million from systems.
The Company delivered 65 U.S. HYDROS systems, including 14 replacements, with new system ASPs around $495,000. Second quarter U.S. procedures exceeded 13,100, up about 21%, with handpiece ASP rising 11% to $3,550. Gross margin improved to 66%, supported by pricing and a $2.9 million tariff refund, while operating expenses increased to $89.8 million. Net loss was $26.9 million (loss per share $0.47), and adjusted EBITDA loss was $11.3 million. Cash, cash equivalents and restricted cash totaled about $231 million at June 30, 2026.
According to the company, full‑year 2026 revenue guidance of $390–$410 million, gross margin of about 65%, U.S. procedure volume of 54,000–56,000, and adjusted EBITDA loss of $35–$30 million is reiterated or updated.
PROCEPT BioRobotics (Nasdaq: PRCT) will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, accessible via webcast and archived for at least 90 days on the company’s investor website.
PROCEPT BioRobotics (Nasdaq: PRCT) reported two key milestones in its WATER IV prostate cancer program: completion of enrollment in the randomized WATER IV RP study comparing Aquablation therapy with radical prostatectomy, and expanded FDA IDE approval for a second randomized WATER IV AS protocol versus active surveillance.
WATER IV RP has fully enrolled 280 patients, with primary endpoint results expected at the AUA Annual Meeting in spring 2027. WATER IV AS will enroll up to 333 patients and, along with WATER IV RP, will follow men for ten years to assess disease control and quality-of-life outcomes.
PROCEPT BioRobotics (Nasdaq: PRCT) announced that updated American Urological Association (AUA) guidelines strengthen the recommendation for Aquablation therapy as a surgical option for men with BPH and prostate volumes of 30–80 mL. The AUA also recognizes Aquablation may be offered for larger prostates of 80–150 mL.
The update reflects maturing clinical evidence, including randomized trials showing durable urinary symptom and flow improvements through five years across a broad range of prostate sizes. Aquablation is supported by trials against TURP and laser enucleation. Earlier this year, European Association of Urology (EAU) guidelines also issued a strong recommendation for Aquablation.
PROCEPT BioRobotics (Nasdaq: PRCT) announced management will present at three investor conferences in May and June 2026: Bank of America Health Care (May 12, Las Vegas), William Blair Growth Stock (June 2, Chicago) and Truist Med‑Tech (June 16, Boston).
Live webcasts and archived recordings will be available on the company Investors website and will remain accessible for at least 90 days after each event.
PROCEPT BioRobotics (Nasdaq: PRCT) reported Q1 2026 results: $83.1M revenue (+20% YoY), ~12,200 U.S. procedures (+30% YoY), 49 U.S. Hydros system sales, and 65% gross margin. Cash and equivalents totaled approximately $249M. The company confirmed full‑year 2026 revenue guidance of $390–$410M and expects U.S. procedure growth of 39–48%.
Q1 net loss was $31.6M with adjusted EBITDA loss of $18.1M; operating expenses increased to $86.6M.